Study population (protocol S8417)
| N = 42 . | |
|---|---|
| Age (y) | 34 (16-73)* |
| Sex (male/female) | 26/16 |
| Race (white/nonwhite) | 36/6 |
| Marrow blasts (%) | 91 (40-99) |
| Marrow lymphs (%) | 3 (0-40) |
| WBC ×103 | 89.9 (2.5-956) |
| Peripheral blasts (%) | 76.5 (0-99) |
| Peripheral blasts ×103 | 48.2 (0-850.8) |
| Peripheral lymphs (%) | 11 (0-80) |
| Peripheral lymphs ×103 | 7.4 (0-86.0) |
| Hemoglobin (g/dL) | 9.4 (4.4-16.3) |
| Platelets ×103 | 48.5 (5-184) |
| p16(INK4A) | |
| Normal | 25 (60%) |
| Abnormal | 17 (41%) |
| Rb | |
| Normal | 20 (49%) |
| Abnormal | 21 (51%) |
| P53 | |
| Normal | 29 (74%) |
| Abnormal | 10 (26%) |
| FAB classification | |
| L1 | 25 (60%) |
| L2 | 14 (33%) |
| L3 | 3 (7%) |
| Blast lineage | |
| B | 23 (55%) |
| T | 6 (14%) |
| Atypical | 3 (7%) |
| Calla + only | 1 (2%) |
| Null | 2 (5%) |
| Unavailable/inevaluable | 7 (17%) |
| Myeloid markers | |
| Negative | 20 (74%) |
| Positive | 7 (26%) |
| CD34 (<20% considered negative) | |
| Negative | 24 (65%) |
| Positive | 13 (35%) |
| Best response | |
| CR | 27 (64%) |
| No CR | 15 (36%) |
| N = 42 . | |
|---|---|
| Age (y) | 34 (16-73)* |
| Sex (male/female) | 26/16 |
| Race (white/nonwhite) | 36/6 |
| Marrow blasts (%) | 91 (40-99) |
| Marrow lymphs (%) | 3 (0-40) |
| WBC ×103 | 89.9 (2.5-956) |
| Peripheral blasts (%) | 76.5 (0-99) |
| Peripheral blasts ×103 | 48.2 (0-850.8) |
| Peripheral lymphs (%) | 11 (0-80) |
| Peripheral lymphs ×103 | 7.4 (0-86.0) |
| Hemoglobin (g/dL) | 9.4 (4.4-16.3) |
| Platelets ×103 | 48.5 (5-184) |
| p16(INK4A) | |
| Normal | 25 (60%) |
| Abnormal | 17 (41%) |
| Rb | |
| Normal | 20 (49%) |
| Abnormal | 21 (51%) |
| P53 | |
| Normal | 29 (74%) |
| Abnormal | 10 (26%) |
| FAB classification | |
| L1 | 25 (60%) |
| L2 | 14 (33%) |
| L3 | 3 (7%) |
| Blast lineage | |
| B | 23 (55%) |
| T | 6 (14%) |
| Atypical | 3 (7%) |
| Calla + only | 1 (2%) |
| Null | 2 (5%) |
| Unavailable/inevaluable | 7 (17%) |
| Myeloid markers | |
| Negative | 20 (74%) |
| Positive | 7 (26%) |
| CD34 (<20% considered negative) | |
| Negative | 24 (65%) |
| Positive | 13 (35%) |
| Best response | |
| CR | 27 (64%) |
| No CR | 15 (36%) |
Median (range).